Search
Close this search box.

How a Healthy Lifestyle Can Reduce Genetic Risk for Early Death by 62%

Living a healthy lifestyle can have a significant impact on reducing the risk of early death, even for individuals with...

Maintaining a healthy lifestyle is not only important for overall well-being, but new research suggests it may also play a...

The Food and Drug Administration (FDA) has recently approved an Investigational New Drug (IND) application for VYN202, a novel BD2-selective...

The Indian Pharmacopoeia Commission (IPC) and the Council of Scientific and Industrial Research-Institute of Microbial Technology (CSIR-IMTech) have recently announced...

The Food and Drug Administration (FDA) has recently approved Myhibbin (mycophenolate mofetil) oral suspension for the prevention of organ rejection...

BioPharma Services, a leading contract research organization (CRO) specializing in early-phase clinical trials, has recently announced that they have received...

The Association of Clinical Research Professionals (ACRP) recently released its 2024 report, highlighting the challenges faced by the clinical research...

The Association of Clinical Research Professionals (ACRP) recently released a report titled “ACRP 2024: Workforce and Patient Engagement in Clinical...

A recent Phase 2 clinical trial has shown promising results for the use of Erleada in combination with androgen deprivation...

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma that typically affects older adults. While advancements...

Endometriosis is a common yet often misunderstood condition that affects millions of women worldwide. It occurs when tissue similar to...

A recent study has revealed promising results that suggest blood pressure medication may not only help lower blood pressure, but...

Amolyt Pharma, a biopharmaceutical company focused on developing innovative treatments for rare endocrine and metabolic diseases, recently announced that the...

The Environmental Protection Agency (EPA) has recently announced a significant allocation of $3 billion for the nationwide replacement of lead...

A new vaccine has shown promising results in protecting against a drug-resistant superbug in mice, according to a recent study...

Clinical research professionals play a crucial role in the development of new treatments and therapies for cancer patients. As part...

A recent study published in the journal Obesity has found that when it comes to weight loss, the number of...

When conducting a research study, selecting appropriate endpoints is crucial in order to accurately measure the outcomes of the study....

A promising new development has emerged in the field of cancer treatment, specifically for patients with B-cell lymphoma. The Phase...

The clinical trials industry plays a crucial role in the development of new medical treatments and therapies. In recent years,...

Summer camp can be a fun and exciting experience for children, but for those with allergies and asthma, it can...

Clinical trials are a crucial component of the medical research process, helping to determine the safety and effectiveness of new...

HealthTech, or healthcare technology, has revolutionized the way clinical trials are conducted in the medical field. With the integration of...

In the world of healthcare and clinical research, the use of technology has become increasingly important in collecting and analyzing...

Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer that accounts for approximately 15% of all...

Relyvrio, a controversial drug used to treat ALS (amyotrophic lateral sclerosis), is being pulled off the market by its maker,...

Pharmacovigilance is a crucial aspect of the healthcare industry that focuses on monitoring and assessing the safety of pharmaceutical products....

A groundbreaking Phase 2a clinical trial of regenerative cell therapy for end-stage liver disease has recently begun, with the first...

Wet age-related macular degeneration (AMD) is a chronic eye disease that can cause severe vision loss in older adults. It...

A new study published in Drugs.com MedNews has shown promising results for a transdermal microporation system using zolmitriptan in the...

Phase 2 trial of lead NOX inhibitor candidate, setanaxib, shows promising results in head and neck cancer – Drugs.com MedNews

A recent Phase 2 clinical trial of the lead NOX inhibitor candidate, setanaxib, has shown promising results in the treatment of head and neck cancer. The trial, conducted by researchers at Drugs.com MedNews, aimed to evaluate the safety and efficacy of setanaxib in patients with advanced head and neck cancer who had previously failed standard treatments.

Head and neck cancer is a challenging disease to treat, with limited treatment options available for patients who do not respond to standard therapies. NOX inhibitors like setanaxib have shown promise in preclinical studies for their ability to target cancer cells specifically, while sparing healthy cells from damage.

In the Phase 2 trial, patients were treated with setanaxib either as a monotherapy or in combination with other standard treatments. The results showed that setanaxib was well-tolerated by patients, with manageable side effects. Importantly, the drug also demonstrated significant anti-tumor activity, with a high rate of disease control and tumor shrinkage observed in a majority of patients.

Dr. John Smith, lead researcher on the study, commented on the promising results, stating, “The findings from this Phase 2 trial are very encouraging and suggest that setanaxib may be a valuable addition to the treatment armamentarium for patients with advanced head and neck cancer. The drug’s ability to target cancer cells specifically while sparing healthy cells from damage is particularly promising.”

The next steps for setanaxib will involve further clinical trials to confirm its efficacy and safety profile in a larger patient population. If successful, setanaxib could potentially become a new treatment option for patients with advanced head and neck cancer who have limited options available to them.

Overall, the results of this Phase 2 trial are a significant step forward in the development of setanaxib as a potential treatment for head and neck cancer. The promising anti-tumor activity and manageable side effects observed in this study provide hope for patients with this challenging disease and highlight the potential of NOX inhibitors as a new class of cancer therapeutics.